Skip to main content
Erschienen in: Acta Neurochirurgica 12/2010

01.12.2010 | Experimental research

Dose-dependent ultrastructural and morphometric alterations after erythropoietin treatment in rat femoral artery vasospasm model

verfasst von: Ismail Ulusal, Rabia Tari, Gulsah Ozturk, Ezgi Aycicek, Fadime Aktar, Kadir Kotil, Turgay Bilge, Talat Kırış

Erschienen in: Acta Neurochirurgica | Ausgabe 12/2010

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Cerebral vasospasm is the common cause of poor outcome after aneurysmal subarachnoid hemorrhage (aSAH). Although many agents are experimentally and clinicaly used to protect or recover from vasospasm, an effective neurotherapeutic drug is still missing. Erythropoietin (EPO) is recently a promising candidate. The aim of this study is to investigate the dose-dependent effects of recombinant human EPO (rhEPO) on arterial wall in a rat femoral artery vasospasm model.

Methods

Thirty two animals were divided into four groups: vasospasm without any treatment (group A), vasospasm +250 IU/kg rhEPO group (group B), vasospasm +500 IU/kg rhEPO group (group C), and control group (group D). Rat femoral artery vasospasm model was used. For groups B and C, 7 days of 250 IU/kg and 500 IU/kg intraperitoneal rhEPO in 0.3 ml saline were administered respectively; and for groups A and D, 0.3 ml saline were administered intraperitoneally without any treatment. After 7 days, histological and morphometric analyses were carried out.

Results

Vasospasm alone group demonstrated the highest vessel wall thicknesses, comparing to other groups (p < 0.001). While for groups B and C, vessel wall thickness values were significantly higher than the control group (p < 0.001), between these two groups, there was no significant difference achieved (p > 0.05).

Conclusion

In our study, there was no significant difference between the two rhEPO treatment groups, but rhEPO treatment was shown to be histologically and morphometrically effective in vasospasm. However, if dosage of EPO treatment is augmented, successful results may be achieved.
Literatur
1.
Zurück zum Zitat Akisu M, Tuzun S, Arslanoglu S, Yalaz M, Kultursay N (2001) Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Med Okayama 55:357–362PubMed Akisu M, Tuzun S, Arslanoglu S, Yalaz M, Kultursay N (2001) Effect of recombinant human erythropoietin administration on lipid peroxidation and antioxidant enzyme(s) activities in preterm infants. Acta Med Okayama 55:357–362PubMed
2.
Zurück zum Zitat Ayer RE, Zhang JH (2008) Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm. Acta Neurochir Suppl 104:33–41CrossRefPubMed Ayer RE, Zhang JH (2008) Oxidative stress in subarachnoid haemorrhage: significance in acute brain injury and vasospasm. Acta Neurochir Suppl 104:33–41CrossRefPubMed
3.
Zurück zum Zitat Banerjee D, Rodriguez M, Nag M, Adamson JW (2000) Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 57:1895–1904CrossRefPubMed Banerjee D, Rodriguez M, Nag M, Adamson JW (2000) Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int 57:1895–1904CrossRefPubMed
4.
Zurück zum Zitat Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT (2004) Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104:2073–2080CrossRefPubMed Beleslin-Cokic BB, Cokic VP, Yu X, Weksler BB, Schechter AN, Noguchi CT (2004) Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. Blood 104:2073–2080CrossRefPubMed
5.
Zurück zum Zitat Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643–651CrossRefPubMed Bernaudin M, Marti HH, Roussel S, Divoux D, Nouvelot A, MacKenzie ET, Petit E (1999) A potential role for erythropoietin in focal permanent cerebral ischemia in mice. J Cereb Blood Flow Metab 19:643–651CrossRefPubMed
6.
Zurück zum Zitat Brines ML, Ghezzi P, Kenan S, Agnello D, de Laner Olle NC, Cerami C et al (2000) Erytropoetin crosses the blood brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(10):526–531 Brines ML, Ghezzi P, Kenan S, Agnello D, de Laner Olle NC, Cerami C et al (2000) Erytropoetin crosses the blood brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97(10):526–531
7.
Zurück zum Zitat Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L (2009) Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci 21(10):7CrossRef Cheng G, Wei L, Zhi-Dan S, Shi-Guang Z, Xiang-Zhen L (2009) Atorvastatin ameliorates cerebral vasospasm and early brain injury after subarachnoid hemorrhage and inhibits caspase-dependent apoptosis pathway. BMC Neurosci 21(10):7CrossRef
8.
Zurück zum Zitat Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L et al (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 103:5965–5970CrossRefPubMed Coleman TR, Westenfelder C, Togel FE, Yang Y, Hu Z, Swenson L et al (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 103:5965–5970CrossRefPubMed
9.
Zurück zum Zitat Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev Jul 18(3):CD000277. Review Dorhout Mees SM, Rinkel GJ, Feigin VL, Algra A, van den Bergh WM, Vermeulen M, van Gijn J (2007) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev Jul 18(3):CD000277. Review
10.
Zurück zum Zitat d’Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS (2007) Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 49:1142–1148CrossRefPubMed d’Uscio LV, Smith LA, Santhanam AV, Richardson D, Nath KA, Katusic ZS (2007) Essential role of endothelial nitric oxide synthase in vascular effects of erythropoietin. Hypertension 49:1142–1148CrossRefPubMed
11.
Zurück zum Zitat Grasso G, Buemi M, Corica F, Calapani G, Salpietro FM, Casuscelli T et al (2000) In vivo evidence that erythtropoetin has a neuro-protective effect during subarachnoid hemorrhage. Eur J Pharmacol 392:31–34CrossRefPubMed Grasso G, Buemi M, Corica F, Calapani G, Salpietro FM, Casuscelli T et al (2000) In vivo evidence that erythtropoetin has a neuro-protective effect during subarachnoid hemorrhage. Eur J Pharmacol 392:31–34CrossRefPubMed
12.
Zurück zum Zitat Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y, Taki W (2008) Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 32:157–161CrossRefPubMed Ito H, Fukunaga M, Suzuki H, Miyakoda G, Ishikawa M, Yabuuchi Y, Taki W (2008) Effect of cilostazol on delayed cerebral vasospasm after subarachnoid hemorrhage in rats: evaluation using black blood magnetic resonance imaging. Neurobiol Dis 32:157–161CrossRefPubMed
13.
Zurück zum Zitat Kern M, Lam MM, Knuckey NW, Lind CR (2009) Statins may not protect against vasospasm in subarachnoid haemorrhage. J Clin Neurosci 16:527–530, Epub 2009CrossRefPubMed Kern M, Lam MM, Knuckey NW, Lind CR (2009) Statins may not protect against vasospasm in subarachnoid haemorrhage. J Clin Neurosci 16:527–530, Epub 2009CrossRefPubMed
14.
Zurück zum Zitat Kiriş T, Karasu A, Yavuz C, Erdem T, Unal F, Hepgül K, Baloğlu H (1999) Reversal of cerebral vasospasm by the nitric oxide donor SNAP in an experimental model of subarachnoid haemorrhage. Acta Neurochir (Wien) 141:1323–1328, discussion 1328–1329CrossRef Kiriş T, Karasu A, Yavuz C, Erdem T, Unal F, Hepgül K, Baloğlu H (1999) Reversal of cerebral vasospasm by the nitric oxide donor SNAP in an experimental model of subarachnoid haemorrhage. Acta Neurochir (Wien) 141:1323–1328, discussion 1328–1329CrossRef
15.
Zurück zum Zitat Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan B (2009) Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 10:157–165CrossRefPubMed Kramer AH, Zygun DA, Bleck TP, Dumont AS, Kassell NF, Nathan B (2009) Relationship between hemoglobin concentrations and outcomes across subgroups of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care 10:157–165CrossRefPubMed
16.
Zurück zum Zitat Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al (2005) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239–242CrossRef Leist M, Ghezzi P, Grasso G, Bianchi R, Villa P, Fratelli M et al (2005) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239–242CrossRef
17.
Zurück zum Zitat Mayberg MR, Okada T, Bark DH (1990) Morphologic changes in cerebral arteries after subarachnoid hemorrhage. Neurosurg Clin N Am 1:417–432PubMed Mayberg MR, Okada T, Bark DH (1990) Morphologic changes in cerebral arteries after subarachnoid hemorrhage. Neurosurg Clin N Am 1:417–432PubMed
18.
Zurück zum Zitat Mayberg MR, Okada T, Bark DH (1990) The significance of morphological changes in cerebral arteries after subarachnoid hemorrhage. J Neurosurg 72:626–633CrossRefPubMed Mayberg MR, Okada T, Bark DH (1990) The significance of morphological changes in cerebral arteries after subarachnoid hemorrhage. J Neurosurg 72:626–633CrossRefPubMed
19.
Zurück zum Zitat Mori K, Miyazaki M, Hara Y, Aiko Y, Yamamoto T, Nakao Y (2009) Novel vasodilatory effect of intracisternal injection of magnesium sulfate solution on spastic cerebral arteries in the canine two-hemorrhage model of subarachnoid hemorrhage. J Neurosurg 110:73–78CrossRefPubMed Mori K, Miyazaki M, Hara Y, Aiko Y, Yamamoto T, Nakao Y (2009) Novel vasodilatory effect of intracisternal injection of magnesium sulfate solution on spastic cerebral arteries in the canine two-hemorrhage model of subarachnoid hemorrhage. J Neurosurg 110:73–78CrossRefPubMed
20.
Zurück zum Zitat Mori K, Miyazaki M, Iwata J, Yamamoto T, Nakao Y (2008) Intracisternal infusion of magnesium sulfate solution improved reduced cerebral blood flow induced by experimental subarachnoid hemorrhage in the rat. Neurosurg Rev 31:197–203, discussion 203CrossRefPubMed Mori K, Miyazaki M, Iwata J, Yamamoto T, Nakao Y (2008) Intracisternal infusion of magnesium sulfate solution improved reduced cerebral blood flow induced by experimental subarachnoid hemorrhage in the rat. Neurosurg Rev 31:197–203, discussion 203CrossRefPubMed
21.
Zurück zum Zitat Murphy AM, Xenocostas A, Pakkiri P, Lee TY (2008) Hemodynamic effects of recombinanthuman erythropoietin on the central nervous system after subarachnoid hemorrhage: reduction of microcirculatory impairment and functional deficits in a rabbit model. J Neurosurg 109:1155–1164CrossRefPubMed Murphy AM, Xenocostas A, Pakkiri P, Lee TY (2008) Hemodynamic effects of recombinanthuman erythropoietin on the central nervous system after subarachnoid hemorrhage: reduction of microcirculatory impairment and functional deficits in a rabbit model. J Neurosurg 109:1155–1164CrossRefPubMed
22.
Zurück zum Zitat Okada T, Harada T, Bark DH, Mayberg MR (1990) A rat femoral artery model for vasospasm. Neurosurgery 27:349–356CrossRefPubMed Okada T, Harada T, Bark DH, Mayberg MR (1990) A rat femoral artery model for vasospasm. Neurosurgery 27:349–356CrossRefPubMed
23.
Zurück zum Zitat Pluta RM (2008) Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Acta Neurochir Suppl 104:139–147, ReviewCrossRefPubMed Pluta RM (2008) Dysfunction of nitric oxide synthases as a cause and therapeutic target in delayed cerebral vasospasm after SAH. Acta Neurochir Suppl 104:139–147, ReviewCrossRefPubMed
24.
Zurück zum Zitat Rinkel GJ, Feigin VL, Algra A, Vermeulen M, van Gijn J (2002) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 4:CD000277 Rinkel GJ, Feigin VL, Algra A, Vermeulen M, van Gijn J (2002) Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev 4:CD000277
25.
Zurück zum Zitat Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C et al (2000) Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97:609–613CrossRef Ruschitzka FT, Wenger RH, Stallmach T, Quaschning T, de Wit C et al (2000) Nitric oxide prevents cardiovascular disease and determines survival in polyglobulic mice overexpressing erythropoietin. Proc Natl Acad Sci USA 97:609–613CrossRef
26.
Zurück zum Zitat Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635–4640CrossRefPubMed Sakanaka M, Wen TC, Matsuda S, Masuda S, Morishita E, Nagao M, Sasaki R (1998) In vivo evidence that erythropoietin protects neurons from ischemic damage. Proc Natl Acad Sci USA 95:4635–4640CrossRefPubMed
27.
Zurück zum Zitat Santhanam AV, Katusic ZS (2006) Erythropoietin and cerebral vascular protection:role of nitric oxide. Acta Pharmacol Sin 27:1389–1394, ReviewCrossRefPubMed Santhanam AV, Katusic ZS (2006) Erythropoietin and cerebral vascular protection:role of nitric oxide. Acta Pharmacol Sin 27:1389–1394, ReviewCrossRefPubMed
28.
Zurück zum Zitat Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS (2005) Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 36:2731–2737CrossRefPubMed Santhanam AV, Smith LA, Akiyama M, Rosales AG, Bailey KR, Katusic ZS (2005) Role of endothelial NO synthase phosphorylation in cerebrovascular protective effect of recombinant erythropoietin during subarachnoid hemorrhage-induced cerebral vasospasm. Stroke 36:2731–2737CrossRefPubMed
29.
Zurück zum Zitat Schubert GA, Schilling L, Thomè C (2008) Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. J Neurosurg 109:1134–1140CrossRefPubMed Schubert GA, Schilling L, Thomè C (2008) Clazosentan, an endothelin receptor antagonist, prevents early hypoperfusion during the acute phase of massive experimental subarachnoid hemorrhage: a laser Doppler flowmetry study in rats. J Neurosurg 109:1134–1140CrossRefPubMed
30.
Zurück zum Zitat Springborg JB, Møller C, Gideon P, Jørgensen OS, Juhler M, Olsen NV (2007) Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 149:1089–1101, discussion 1101CrossRef Springborg JB, Møller C, Gideon P, Jørgensen OS, Juhler M, Olsen NV (2007) Erythropoietin in patients with aneurysmal subarachnoid haemorrhage: a double blind randomised clinical trial. Acta Neurochir (Wien) 149:1089–1101, discussion 1101CrossRef
31.
Zurück zum Zitat Springborg JB, Sonne B, Frederiksen HJ, Foldager N, Poulsgaard L, Klausen T, Jorgensen OS, Olsen NV (2003) Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain. Brain Res 984:143–148CrossRefPubMed Springborg JB, Sonne B, Frederiksen HJ, Foldager N, Poulsgaard L, Klausen T, Jorgensen OS, Olsen NV (2003) Erythropoietin in the cerebrospinal fluid of patients with aneurysmal subarachnoid haemorrhage originates from the brain. Brain Res 984:143–148CrossRefPubMed
32.
Zurück zum Zitat Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP (1999) Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 127:482–488CrossRefPubMed Squadrito F, Altavilla D, Squadrito G, Campo GM, Arlotta M, Quartarone C, Saitta A, Caputi AP (1999) Recombinant human erythropoietin inhibits iNOS activity and reverts vascular dysfunction in splanchnic artery occlusion shock. Br J Pharmacol 127:482–488CrossRefPubMed
33.
Zurück zum Zitat Sugawara T, Ayer R, Zhang JH (2008) Role of statins in cerebral vasospasm. Acta Neurochir Suppl 104:287–290CrossRefPubMed Sugawara T, Ayer R, Zhang JH (2008) Role of statins in cerebral vasospasm. Acta Neurochir Suppl 104:287–290CrossRefPubMed
34.
Zurück zum Zitat Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K (2008) Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 48:241–247, discussion 247–248CrossRef Suzuki Y, Shibuya M, Satoh S, Sugiyama H, Seto M, Takakura K (2008) Safety and efficacy of fasudil monotherapy and fasudil-ozagrel combination therapy in patients with subarachnoid hemorrhage: sub-analysis of the post-marketing surveillance study. Neurol Med Chir (Tokyo) 48:241–247, discussion 247–248CrossRef
35.
Zurück zum Zitat Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ (2009) Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. J Neurosurg 111:171–180CrossRefPubMed Tseng MY, Hutchinson PJ, Richards HK, Czosnyka M, Pickard JD, Erber WN, Brown S, Kirkpatrick PJ (2009) Acute systemic erythropoietin therapy to reduce delayed ischemic deficits following aneurysmal subarachnoid hemorrhage: a Phase II randomized, double-blind, placebo-controlled trial. J Neurosurg 111:171–180CrossRefPubMed
36.
Zurück zum Zitat Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L (2007) Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 27:552–563CrossRefPubMed Villa P, van Beek J, Larsen AK, Gerwien J, Christensen S, Cerami A, Brines M, Leist M, Ghezzi P, Torup L (2007) Reduced functional deficits, neuroinflammation, and secondary tissue damage after treatment of stroke by nonerythropoietic erythropoietin derivatives. J Cereb Blood Flow Metab 27:552–563CrossRefPubMed
37.
Zurück zum Zitat Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT (2006) Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 5:71–78CrossRefPubMed Wang H, Gao J, Lassiter TF, McDonagh DL, Sheng H, Warner DS, Lynch JR, Laskowitz DT (2006) Levetiracetam is neuroprotective in murine models of closed head injury and subarachnoid hemorrhage. Neurocrit Care 5:71–78CrossRefPubMed
Metadaten
Titel
Dose-dependent ultrastructural and morphometric alterations after erythropoietin treatment in rat femoral artery vasospasm model
verfasst von
Ismail Ulusal
Rabia Tari
Gulsah Ozturk
Ezgi Aycicek
Fadime Aktar
Kadir Kotil
Turgay Bilge
Talat Kırış
Publikationsdatum
01.12.2010
Verlag
Springer Vienna
Erschienen in
Acta Neurochirurgica / Ausgabe 12/2010
Print ISSN: 0001-6268
Elektronische ISSN: 0942-0940
DOI
https://doi.org/10.1007/s00701-010-0775-6

Weitere Artikel der Ausgabe 12/2010

Acta Neurochirurgica 12/2010 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.